Apr 30, 2020
InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755
Apr 01, 2020
InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
Mar 24, 2020
InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial
Mar 20, 2020
InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak
Mar 10, 2020
InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
Jan 21, 2020
InMed Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview
Jan 20, 2020
InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials
Jan 16, 2020
InMed Pharmaceuticals to Attend and Exhibit at EB2020 World Congress
Jan 07, 2020
Aegle Therapeutics Announces $4M Financing to Fund Groundbreaking Stem Cell Exosome Clinical Trial to Treat Orphan Disease Dystrophic Epidermolysis Bullosa
Dec 09, 2019
InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa
Dec 04, 2019
FDA Grants Orphan Drug Designation to APR Applied Pharma Research's Investigational Drug for the Treatment of Epidermolysis Bullosa
Nov 18, 2019
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Abeona Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ABEO
Nov 05, 2019
InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial
Aug 08, 2019
Butterfly Children: Epidermolysis Bullosa and Anesthesia
Jul 29, 2019
RegeneRx's RGN-137 for Epidermolysis Bullosa Subject of New Article in Seeking Alpha Investor Site
Jul 03, 2019
Rongxiang Xu Regenerative Life Non-Profit Fund Joined the Rare Disease Care Movement of Chinese Red Cross Foundation -- Launched "Butterfly Baby Rescue Plan"
May 20, 2019
Aegle Therapeutics Corp. Receives IND Clearance from FDA for Its MSC-Derived Extracellular Vesicle Therapy for Dystrophic Epidermolysis Bullosa
Apr 30, 2019
Phoenix Tissue Repair Receives FDA Fast Track Designation for PTR-01 for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) and Provides Updates on the Phase 1/2 Clinical Study
Feb 22, 2019
Phoenix Tissue Repair Doses First Patient in Phase 1/2 Clinical Trial of PTR-01 (BBP-589) for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Feb 12, 2019
InMed Pharmaceuticals Reports Second Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update